Bandingkan Harga & Kinerja Indofarma Tbk. (INAF) vs Reksa Dana Syariah BRI MI Gold ETF Syariah (XDES)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Indofarma Tbk. dan Reksa Dana Syariah BRI MI Gold ETF Syariah: Indofarma Tbk. diperdagangkan di Rp126 (kapitalisasi pasar 390,51 M), sedangkan Reksa Dana Syariah BRI MI Gold ETF Syariah diperdagangkan di Rp987 (kapitalisasi pasar 4,45 M, volume 24 jam 119,3 rb). Perbedaan utamanya: Indofarma Tbk. jauh lebih besar — sekitar 87,8× kapitalisasi pasar Reksa Dana Syariah BRI MI Gold ETF Syariah. Mana yang lebih baik tergantung tujuan investasimu.
| INAF | XDES | |
|---|---|---|
Kapitalisasi Pasar | 390,51 M | 4,45 M |
Volume | — | 119,3 rb |
Lot | — | 1,19 rb |
Perputaran | — | 110,01 jt |
Harga Rata-rata | — | 922,09 |
Nilai Transaksi | — | 110,01 jt |
Harga Ekuilibrium Indikatif | — | 987 |
Volume Ekuilibrium Indikatif | — | 1 |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Indofarma Tbk.
PT Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk (the Company) was established based on Deed No. 1 dated January 2, 1996 as amended by Deed No. 134 dated January 26, 1996 both of Notary Sutjipto, SH. PT. Indofarma, Tbk began as medicine factory well known as "Pabrik Obat Manggarai". Then take over by Japan's Government from Nederland's Government on 1942. On 1950 the Indonesian Government acquisited the factory by Department of Health and functioned as center of pharmacy production for its department. On 1979 the name changed to be Department of Health Center of Pharmacy Production as non Profit institution as main assignment to produced medicine for public service. Then the Company changed the name as PT. Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk.
Selengkapnya di halaman INAF →
